Live data from Hacker News

Accelerating scientific breakthroughs with an AI co-scientist

research.google

31–40 of 202 posts

Re: Accelerating scientific breakthroughs with an AI co-scientist

#31

“Drug repurposing for AML” lol As a person who is literally doing his PhD on AML by implementing molecular subtyping, and ex-vivo drug predictions. I find this super random. I would truly suggest our pipeline instead of random drug repurposing :) https://celvox.co/solutions/seAMLess edit: Btw we’re looking for ways to fund/commercialize our pipeline. You could contact us through the site if you’re interested!

It's almost like scientists are doing something more than a random search over language.

Re: Accelerating scientific breakthroughs with an AI co-scientist

#32

It seems in general we’re heading toward’s Minsky’s society of minds concept. I know OpenAI is wanting to collapse all their models into a single omni model that can do it all, but I wonder if under the hood it’d just be about routing. It’d make sense to me for agents to specialize in certain tool calls, ways of thinking, etc that as a conceptual framework/scaffolding provides a useful direction.

I wonder if OpenAI might be routing already based on speed of some "O1" responses I receive. It does make sense.

Re: Accelerating scientific breakthroughs with an AI co-scientist

#33
So I'm a biomedical scientist (in training I suppose...I'm in my 3rd year of a Genetics PhD) and I have seen this trend a couple of times now where AI developers tout that AI will accelerate biomedical discovery through a very specific argument that AI will be smarter and generate better hypotheses than humans.

For example in this Google essay they make the claim that CRISPR was a transdisciplinary endeavor, "which combined expertise ranging from microbiology to genetics to molecular biology" and this is the basis of their argument that an AI co-scientist will be better able to integrate multiple fields at once to generate novel and better hypothesis. For one, what they fail to understand as computer scientists (I suspect due to not being intimately familiar with biomedical research) is that microbio/genetics/mol bio are closer linked than you may expect as a lay person. There is no large leap between microbiology and genetics that would slow down someone like Doudna or even myself - I use techniques from multiple domains in my daily work. These all fall under the general broad domain of what I'll call "cellular/micro biology". As another example, Dario Amodei from Claude also wrote something similar in his essay Machines of Loving Grace that the limiting factor in biomedical is a lack of "talented, creative researchers" for which AI could fill the gap[1].

The problem with both of these ideas is that they misunderstand the rate-limiting factor in biomedical research. Which to them is a lack of good ideas. And this is very much not the case. Biologists have tons of good ideas. The rate limiting step is testing all these good ideas with sufficient rigor to either continue exploring that particular hypothesis or whether to abandon the project for something else. From my own work, the hypothesis driving my thesis I came up with over the course of a month or two. The actual amount of work prescribed by my thesis committee to fully explore whether or not it was correct? 3 years or so worth of work. Good ideas are cheap in this field.

Overall I think these views stem from field specific nuances that don't necessarily translate. I'm not a computer scientist, but I imagine that in computer science the rate limiting factor is not actually testing out hypothesis but generating good ones. It's not like the code you write will take multiple months to run before you get an answer to your question (maybe it will? I'm not educated enough about this to make a hard claim. In biology, it is very common for one experiment to take multiple months before you know the answer to your question or even if the experiment failed and you have to do it again). But happy to hear from a CS PhD or researcher about this.

All this being said I am a big fan of AI. I try and use ChatGPT all the time, I ask it research questions, ask it to search the literature and summarize findings, etc. I even used it literally yesterday to make a deep dive into a somewhat unfamiliar branch of developmental biology more easy (and I was very satisfied with the result). But for scientific design, hypothesis generation? At the moment, useless. AI and other LLMs at this point are a very powerful version of google and code writer. And it's not even correct 30% of the time to boot so you have to be extremely careful when using it. I do think that wasting less time exploring hypotheses that are incorrect or bad is a good thing. But the problem here is that we can pretty easily identify good and bad hypotheses already. We don't need AI for that, what takes time is the actual amount of testing of these hypotheses that slows down research. Oh and politics, which I doubt AI can magic away for us.

[1] https://darioamodei.com/machines-of-loving-grace#1-biology-a...

Re: Accelerating scientific breakthroughs with an AI co-scientist

#34

I'm not sure if people here even read the entirety of the article. From the article: > We applied the AI co-scientist to assist with the prediction of drug repurposing opportunities and, with our partners, validated predictions through computational biology, expert clinician feedback, and in vitro experiments. > Notably, the AI co-scientist proposed novel repurposing candidates for acute myeloid leukemia (AML). Subse…

That a UPR inhibitor would inhibit viability of AML cell lines is not exactly a novel scientific hypothesis. They took a previously published inhibitor known to be active in other cell lines and tried it in a new one. It's a cool, undergrad-level experiment. I would be impressed if a sophomore in high school proposed it, but not a sophomore in college.

Re: Accelerating scientific breakthroughs with an AI co-scientist

#35
post #27

“Drug repurposing for AML” lol As a person who is literally doing his PhD on AML by implementing molecular subtyping, and ex-vivo drug predictions. I find this super random. I would truly suggest our pipeline instead of random drug repurposing :) https://celvox.co/solutions/seAMLess edit: Btw we’re looking for ways to fund/commercialize our pipeline. You could contact us through the site if you’re interested!

Can you explain what you mean by subtyping and if/how it negates the usefulness of repurposing (if that’s what you meant to say). Wouldn’t subtyping complement a drug repurposing screen by allowing the scientist to test compounds against a subset of a disease? And drug repurposing is also used for conditions with no known molecular basis like autism. You’re not suggesting its usefulness is limited in those cases righ…

Sure. There are studies like BEAT-AML which tests selected drugs’ responses on primary AML material. So, not on a cell-line but on true patient data. Combining this information with molecular measurements, you can actually say something about which drugs would be useful for a subset of the patients.

However, this is still not how you treat a patient. There are standard practices in the clinic. Usually the first line treatment is induction chemo with hypomethylating agents (except elderly who might not be eligible for such a treatment). Otherwise the options are still very limited, the “best” drug in the field so far is a drug called Venetoclax, but more things are coming up such as immuno-therapy etc. It’s a very complex domain, so drug repurposing on an AML cell line is not a wow moment for me.

Re: Accelerating scientific breakthroughs with an AI co-scientist

#36

I'm not sure if people here even read the entirety of the article. From the article: > We applied the AI co-scientist to assist with the prediction of drug repurposing opportunities and, with our partners, validated predictions through computational biology, expert clinician feedback, and in vitro experiments. > Notably, the AI co-scientist proposed novel repurposing candidates for acute myeloid leukemia (AML). Subse…

Similar stuff is being done for material sciences where AI suggest different combinations to find different properties. So when people say AI(machine learning, LLM) are just for show I am a bit shocked as AI's today have accelerated discoveries in many different fields of science and this is just the start. Anna archive probably will play a huge role in this as no human or even a group of humans will have all the knowledge of so many fields that an Ai will have.

https://www.independent.co.uk/news/science/super-diamond-b26...

Re: Accelerating scientific breakthroughs with an AI co-scientist

#37

I'm not sure if people here even read the entirety of the article. From the article: > We applied the AI co-scientist to assist with the prediction of drug repurposing opportunities and, with our partners, validated predictions through computational biology, expert clinician feedback, and in vitro experiments. > Notably, the AI co-scientist proposed novel repurposing candidates for acute myeloid leukemia (AML). Subse…

That a UPR inhibitor would inhibit viability of AML cell lines is not exactly a novel scientific hypothesis. They took a previously published inhibitor known to be active in other cell lines and tried it in a new one. It's a cool, undergrad-level experiment. I would be impressed if a sophomore in high school proposed it, but not a sophomore in college.

Only two years since chatGPT was released and AI at the level of "impressive high school sophomore" is already blasé.

Re: Accelerating scientific breakthroughs with an AI co-scientist

#38
post #9

Earlier quoted context omitted.

Are you a scientist?

It is obvious that scientists are afraid for their job, that mere lab technicians will now be sufficient.

Sure, as soon as managers replace software engineers by spending their working hours prompting LLMs.

Re: Accelerating scientific breakthroughs with an AI co-scientist

#39

I'm not sure if people here even read the entirety of the article. From the article: > We applied the AI co-scientist to assist with the prediction of drug repurposing opportunities and, with our partners, validated predictions through computational biology, expert clinician feedback, and in vitro experiments. > Notably, the AI co-scientist proposed novel repurposing candidates for acute myeloid leukemia (AML). Subse…

Not that I don't think there's a lot of potential in this approach, but the leukemia example seemed at least poorly-worded, "the suggested drugs inhibit tumor viability" reads oddly given that blood cancers don't form tumors?

Health professionals often refer to leukemia and lymphoma as "liquid tumors"

Re: Accelerating scientific breakthroughs with an AI co-scientist

#40

I'm not sure if people here even read the entirety of the article. From the article: > We applied the AI co-scientist to assist with the prediction of drug repurposing opportunities and, with our partners, validated predictions through computational biology, expert clinician feedback, and in vitro experiments. > Notably, the AI co-scientist proposed novel repurposing candidates for acute myeloid leukemia (AML). Subse…

That a UPR inhibitor would inhibit viability of AML cell lines is not exactly a novel scientific hypothesis. They took a previously published inhibitor known to be active in other cell lines and tried it in a new one. It's a cool, undergrad-level experiment. I would be impressed if a sophomore in high school proposed it, but not a sophomore in college.

> I would be impressed if a sophomore in high school proposed it

That sounds good enough for a start, considering you can massively parallelize the AI co-scientist workflow, compared to the timescale and physical scale it would take to do the same thing with human high school sophomores.

And every now and then, you get something exciting and really beneficial coming from even inexperienced people, so if you can increase the frequency of that, that sounds good too.

Post reply on HN